H.C. Wainwright analyst Yi Chen reiterated a Buy rating on OpGen (OPGN – Research Report) today and set a price target of $3.00. The company’s shares closed last Thursday at $0.48, close to its 52-week low of $0.31.
According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -11.0% and a 31.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.
Currently, the analyst consensus on OpGen is a Moderate Buy with an average price target of $3.00.
The company has a one-year high of $3.72 and a one-year low of $0.31. Currently, OpGen has an average volume of 406.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OpGen, Inc. engages in the development of molecular information products and services for global healthcare settings. It helps to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
Read More on OPGN:
- H.C. Wainwright Sticks to Its Buy Rating for Safe Bulkers (SB)
- Analysts Conflicted on These Healthcare Names: Meridian Bioscience (VIVO), Puma Biotechnology (PBYI) and Roche Holding AG (OtherRHHVF)
- Berenberg Bank Thinks Callaway Golf’s Stock is Going to Recover
- Net Asset Value(s)
- Form 8.3 – Ideagen PLC